Thyroid eye disease remains one of the most challenging extrathyroidal manifestations of Graves' disease, with the potential to significantly affect vision, appearance, and quality of life. Recent therapeutic advances have shifted management beyond traditional immunosuppressive approaches, introducing targeted therapies that address disease pathophysiology more directly. Here is a quick question on contemporary management of thyroid eye disease! (Scroll down to answer the question) ##Reference## Xu Z, Hu N, Chen Q, Zhou Y, Huang Y, Hu S, Jin H, Tang Y. Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review.
Front Endocrinol (Lausanne). 2025 May 27;16:1480195. doi: 10.3389/fendo.2025.1480195. PMID: 40496563; PMCID: PMC12148721. ## ##Disclaimer## The content provided on Docplexus is intended for educational purposes only.…
